Posted on 23/04/2010 in Medical Company Financials Genzyme has published its financial report for the first quarter of 2010, which highlighted year-on-year growth in sales of its biosurgery products.
The company earned a total of $79.5 million (51.7 million pounds) from sales of its Synvisc viscosupplement range in the three-month period, an increase of 26 per cent compared to last year.
In addition, improved sales of the Seprafilm adhesion barrier in C-section and other gynaecological procedures helped to drive sales of the Sepra range up by eight per cent to $37.2 million.
Across the company as a whole, revenues declined slightly from $1.2 billion to $1.1 billion, which was attributed to limited supply of key Genzyme products Cerezyme and Fabrazyme.
Henri Termeer, Genzyme's chairman and chief executive officer, stated that the firm will now be looking to resume sustainable growth by "transforming our manufacturing operations, maximising the potential of our diverse product portfolio and advancing key pipeline programmes".
Last week, it was announced that Genzyme will be partnering with Arecor in order to develop a new range of protein-based therapeutics.Other news stories from 23/04/2010
Read more in the Zenopa News Archive
How this news is generated
|
